IL6 and rheumatic disorder: Passive immunization aimed at neutralizing the pathogenic cytokines such as TNF-α and IL-6 with monoclonal antibodies (mAbs) or soluble receptors has been proven to be an effective therapy strategy of rheumatic diseases such as RA and AS [5].